It could be argued that statins, besides a weak direct antiviral effect, may enhance HCV infectivity of hepatocytes through the decrease in circulating LDL levels and the up-regulation of LDL receptors. This effect of statins might counterbalance the antiviral activity described in the replicon models.The promising results, however statistically insignificant, obtained in this study and that supported with significant results of Kondo and his colleague that was published recently in late 2012, hopefully will invite further interest for planning studying the synergistic role for statins added to standard therapy and possibly adding to the triple combination of protease/ polymerase inhibitor, peginterferon and ribavirin may improve the impressive SVRs of these medications.